Trifecta-Heart cfDNA-MMDx Study

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions
Heart Transplant Rejection
Interventions
DIAGNOSTIC_TEST

MMDx diagnostic test

Microarray test of gene expression in heart biopsies

DIAGNOSTIC_TEST

Prospera

Donor derived cell-free DNA in patient blood

DIAGNOSTIC_TEST

HLA antibody

Centralized measurement of HLA antibodies in patient blood

Trial Locations (12)

10032

RECRUITING

Columbia University Medical Center, Columbia Interventional Cardiovascular Care, West New York

10467

RECRUITING

Montefiore Medical Center, 3319 Rochambeau Avenue, 2nd FL, The Bronx

33606

NOT_YET_RECRUITING

Tampa General Hospital, 409 Bayshore Blvd., Tampa

40138

NOT_YET_RECRUITING

Heart Failure and Heart Transplant Unit, University of Bologna, Bologna

72205

RECRUITING

Baptist Health Institute for Research and Innovation, Little Rock

75246

RECRUITING

Annette C. and Harold C. Simmons Transplant Institute, BaylorScott&White Research Institute, Dallas

84132

RECRUITING

Cardiovascular Medicine, University of Utah Health, Salt Lake City

NSW 2010

NOT_YET_RECRUITING

Cardiac Transplantation Laboratory, The Victor Chang Cardiac Research Institute, Darlinghurst

T6G 2R7

RECRUITING

Division of Cardiology, University of Alberta, Edmonton

140 21

RECRUITING

Institute for Clinical and Experimental Medicine - IKEM Videnska 1958/9, Prague

41-800

RECRUITING

Silesian Center for Heart Diseases (Ś!ąskie Centrum Chorób Serca w Zabrzu, Zabrze

Unknown

NOT_YET_RECRUITING

Advanced Heart Failure Transplant Unit, A Coruña

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Natera, Inc.

INDUSTRY

collaborator

One Lambda

UNKNOWN

lead

University of Alberta

OTHER

NCT04707872 - Trifecta-Heart cfDNA-MMDx Study | Biotech Hunter | Biotech Hunter